Prenetics Global Ltd. — FY2022 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2022. This annual filing reports full-year results, not standalone fourth-quarter results. Financial statements are prepared under IFRS and presented in U.S. dollars.
Business context
Prenetics is a Hong Kong-based genomics and diagnostics company. Its offerings include CircleDNA consumer genetic tests, COVID-19 testing, ColoClear colorectal cancer screening, at-home health testing, and—following its December 2022 acquisition of a 74.39% interest in ACT Genomics—precision oncology tests. Prenetics completed its public-company business combination in May 2022.
Key financial metrics
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $275.8 million | $275.9 million |
| Gross profit | $131.6 million | $106.1 million |
| Gross margin | 47.7% | 38.5% |
| Loss from operations | $23.3 million | $10.2 million |
| Net loss | $190.5 million | $174.0 million |
| Net cash from operating activities | $14.5 million | $13.4 million |
| Cash and cash equivalents at year-end | $146.7 million | $35.3 million |
- Revenue mix: Diagnostics generated $260.0 million, approximately 94% of revenue; Prevention generated $15.8 million. Diagnostics revenue was primarily COVID-19 testing. Prevention revenue declined 5% year over year.
- Cash flows: Investing activities used $46.1 million, including purchases of financial assets and short-term deposits, capital expenditure, and the ACT acquisition. Financing activities provided $143.3 million, mainly from $146.2 million of reverse-recapitalization proceeds.
- Debt and liquidity: Year-end lease liabilities were $6.6 million. Trade financing was fully repaid by year-end. The balance sheet also included $3.6 million of warrant liabilities and a $17.1 million current liability for puttable financial instruments related to ACT’s non-controlling shareholders. Management said existing cash should meet operating and capital needs for the foreseeable future, while noting future financing needs depend on growth and investment plans.
- Other balance-sheet items: Total assets were $312.1 million, total liabilities $68.7 million, and equity $243.5 million at December 31, 2022.
Material changes versus FY2021
- Revenue was essentially flat, but regional mix shifted: Hong Kong revenue rose to $210.9 million from $124.9 million, while U.K. revenue fell to $64.8 million from $150.9 million. Management attributed diagnostics growth primarily to Hong Kong government COVID-19 testing awards.
- Lower direct costs improved gross margin by 9.2 percentage points. Selling and distribution expenses fell 39% to $13.3 million; R&D expenses rose 47% to $15.5 million; administrative and other operating expenses rose 14% to $96.1 million.
- Operating loss increased to $23.3 million. FY2022 net loss included $89.5 million of non-cash listing-related share-based payment expense, $60.1 million of fair-value loss on preference-share liabilities, and $30.4 million of diagnostic-business restructuring and impairment costs. These items materially affect comparison of reported losses.
- Prenetics acquired ACT Genomics on December 30 for consideration valued at $49.8 million, comprising $9.0 million cash paid, $0.96 million deferred cash consideration, and 19.9 million shares valued at $39.8 million. The acquisition added $33.8 million of goodwill.
Outlook, management commentary, risks and unusual items
- Prenetics said COVID-19 testing demand had substantially declined as public-health requirements changed. It expects to refocus on genomics and precision oncology, but provided no quantitative revenue, earnings, or cash-flow guidance and expects net losses to continue for the foreseeable future.
- Management described a post-December 2022 restructuring that reduced the global workforce by approximately 60%, with annual headcount-reduction costs of approximately $10 million. The filing also records $30.4 million of FY2022 diagnostic-business restructuring and impairment costs, including impairment of intangible assets, goodwill and property, plant and equipment, plus a prepayment write-off.
- Management expects near-term investment in R&D and commercialization; it also expects lower COVID-related costs as testing volumes diminish. ACT integration, product adoption, regulatory approvals, reimbursement or market access, and the ability to replace COVID-related revenue are significant execution uncertainties. ACTOnco received FDA clearance in January 2023, after year-end.
- Other key risks include intense competition, privacy and cybersecurity exposure involving sensitive genetic and health data, reliance on limited suppliers, customer concentration, and possible need for additional capital. The two largest customers represented approximately 28% and 27% of FY2022 revenue; the largest customer accounted for 56% of year-end trade receivables.
- The company reported no pending legal claims that management viewed as likely to have a material adverse effect. Management concluded disclosure controls and internal control over financial reporting were effective as of year-end; the filing did not include an auditor attestation on internal controls due to the newly public company transition period.
Important facts for investors to verify
- How quickly COVID-19 testing revenue declines, and whether CircleDNA, ColoClear, Circle Snapshot and ACT Genomics can replace it with recurring, profitable revenue.
- ACT’s post-acquisition performance, integration costs and synergies; also verify the terms and potential exercise of the put options held by ACT’s remaining shareholders.
- The composition and recoverability of receivables, particularly given the large customer concentration, and the timing of cash collection from government and corporate customers.
- The nature and recurrence of restructuring charges, impairments, share-based compensation and fair-value movements that drove the reported net loss.
- Cash use after year-end, the remaining repurchase-program authorization, and potential share dilution from acquisition consideration, outstanding warrants and equity awards. The company authorized up to $20 million of repurchases and reported 1,684,757 shares repurchased by the filing date.
- Governance and voting control: the dual-class structure gives Class B shares 20 votes each; CEO Danny Yeung held approximately 76.7% of voting power as of April 18, 2023.